Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
复制标题
血清 KL-6（一种粘蛋白样糖蛋白）作为乳腺癌肿瘤标志物的评估。
DOI：
10.1007/s41480-013-0014-x
复制
发表时间：
2000
期刊：
影响因子：
--
通讯作者：
K. Hirakawa
中科院分区：
文献类型：
--
作者：
Y. Ogawa;T. Ishikawa;K. Ikeda;B. Nakata;T. Sawada;K. Ogisawa;Y. Kato;K. Hirakawa
本研究评估了血清KL - 6作为乳腺癌肿瘤标志物的效用。采用夹心酶免疫测定法对146例乳腺癌患者、13例乳腺良性疾病患者和108例健康个体的血清进行KL - 6滴度测定。同时对患者的相同血清进行癌胚抗原（CEA）和糖类抗原15 - 3（CA15 - 3）滴度检测。原发性乳腺癌患者的平均KL - 6滴度为673单位/毫升，显著高于乳腺良性疾病患者和健康个体（分别为P = 0.037和P < 0.0001）。复发性乳腺癌患者的滴度为1964单位/毫升，也高于原发性乳腺癌患者（P = 0.013）。KL - 6滴度与肿瘤分期、远处转移和复发部位相关（分别为P = 0.0053、P < 0.0001和P = 0.0251）。以467单位/毫升为临界值，KL - 6对原发性乳腺癌的敏感性为31%（I期为16%，II期为29%），对复发性乳腺癌的敏感性为73%（局部复发为50%，远处复发为89%）。特异性为92%。KL - 6的敏感性高于CA15 - 3和CEA。三种标志物联合使用，其次是KL - 6和CEA联合，提高了原发性乳腺癌的敏感性。单独使用KL - 6对复发性乳腺癌的敏感性高于各种联合使用的情况。总之，血清KL - 6作为乳腺癌的肿瘤标志物可能对临床应用有帮助，尤其在疾病复发监测中可能发挥重要作用。
The utility of serum KL-6 as a tumor marker for breast cancer was evaluated in this study. The sera from 146 patients with breast cancer, 13 with benign breast disease, and 108 healthy individuals were measured for KL-6 titer using a sandwich enzyme immunoassay method. Carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3) titers were also tested in the same sera from the patients. The mean KL-6 titer of patients with primary breast cancer was 673 units/ml, which was significantly higher than that of benign and healthy individuals (P = 0.037 and P < 0.0001, respectively). The titer of patients with relapsed breast cancer was 1964 units/ml, which was also higher than that of primary cancer (P = 0.013). KL-6 titer was related to tumor stage, distant metastasis, and relapse site (P = 0.0053, P < 0.0001, and P = 0.0251, respectively). Using the cutoff value of 467 units/ml, the sensitivity of KL-6 was 31% for primary breast cancer (16% for stage I and 29% for stage II) and 73% for relapsed breast cancer (50% for local relapse and 89% for distant relapse). The specificity was 92%. The sensitivity of KL-6 was higher than that of CA15-3 and CEA. Combination of the three markers, followed by KL-6 and CEA, raised the sensitivity for primary breast cancer. Single use of KL-6 demonstrated a higher sensitivity than in each combination for relapsed breast cancer. In conclusion, serum KL-6 may be helpful for clinical use as a tumor marker for breast cancer, and it may play an important role, especially in the surveillance of disease relapse.
浸润性乳腺癌的预后指标。
DOI：
10.1016/s0039-6109(16)45226-6
发表时间：
1990
期刊：
The Surgical clinics of North America
影响因子：
--
作者：
Sunderland,MC;McGuire,WL
通讯作者：
McGuire,WL
影响因子：
45.3
作者：
HAYES, DF;ZURAWSKI, VR;KUFE, DW
通讯作者：
KUFE, DW